Literature DB >> 21842371

Incorporation of innate immune effector mechanisms in the formulation of a vaccine against HIV-1.

Aftab A Ansari1, Ann E Mayne, Yoshiaki Takahashi, Kovit Pattanapanyasat.   

Abstract

The realization of a major role for events that occur during acute viremia that dictate the course of disease both in HIV-1 infected humans and susceptible SIV infected non-human primates has prompted an intense interest in studies of the contribution of innate immune effector mechanisms. It is reasoned that findings from such studies may be important and need to be incorporated into the design and formulation of potential candidate vaccines against HIV-1. This review serves to outline the various non-human primate models that can best serve to address this issue, a summary of our knowledge on the various subsets of NK cells (one of the major innate immune cell lineage) that have an impact on the course of disease, the potential pathways that regulate their function and the potential role of the KIRs on SIV-induced disease course. Finally, the major points from this report and the data presented on similar subjects by other investigators is utilized to provide a summary of the potential future directions that we need to take in efforts to move this field forward.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21842371     DOI: 10.1007/978-1-4419-5632-3_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques.

Authors:  Namal P M Liyanage; Shari N Gordon; Melvin N Doster; Poonam Pegu; Monica Vaccari; Nebiyu Shukur; Luca Schifanella; Cynthia A Pise-Masison; Danuta Lipinska; Kamil Grubczak; Marcin Moniuszko; Genoveffa Franchini
Journal:  Virology       Date:  2014-01-21       Impact factor: 3.616

2.  Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction.

Authors:  Egidio Brocca-Cofano; David Kuhrt; Basile Siewe; Cuiling Xu; George S Haret-Richter; Jodi Craigo; Celia Labranche; David C Montefiori; Alan Landay; Cristian Apetrei; Ivona Pandrea
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

3.  In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Authors:  Yoshiaki Takahashi; Siddappa N Byrareddy; Christina Albrecht; Markus Brameier; Lutz Walter; Ann E Mayne; Paul Dunbar; Robert Russo; Dawn M Little; Tara Villinger; Ladawan Khowawisetsut; Kovit Pattanapanyasat; Francois Villinger; Aftab A Ansari
Journal:  PLoS Pathog       Date:  2014-03-06       Impact factor: 6.823

4.  HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data.

Authors:  Ann M Dennis; Stéphane Hué; Dana Pasquale; Sonia Napravnik; Joseph Sebastian; William C Miller; Joseph J Eron
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

5.  Controlling the HIV/AIDS epidemic: current status and global challenges.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

6.  In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.

Authors:  Yoshiaki Takahashi; Ann E Mayne; Ladawan Khowawisetsut; Kovit Pattanapanyasat; Dawn Little; Francois Villinger; Aftab A Ansari
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.